Advanced Filters
noise
Found 922 clinical trials
R Rebekah J Walker, PhD

Cardiovascular Risk Reduction for Adults With Food Insecurity Using Structured Incentives

The overarching aim of this proposal is to test the efficacy and cost-effectiveness of CVD-FIT, a novel, multi-component intervention that includes three components: 1) monthly income supplementation; 2) weekly structured incentive for the purchase of healthy food options; and 3) evidence-based telephone delivered CVD risk reduction education and skills training …

18 years of age All Phase N/A
A A Strijdhorst

Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which can affect any organ or system in the body. Recently, concerns have also risen about cardiovascular effects of ICI. Retrospective studies …

50 years of age All Phase N/A
A Ashton Krogman

HTN App for HTN Control and Cardiovascular Health Among African-Americans

The purpose of this study is to test the hypertension (HTN) app-based intervention to see if it is more effective in improving uncontrolled HTN and HTN self-care among Africian-Americans from baseline to post-intervention (immediate, 3 months and 6 months post-intervention) as compared to the standard of care.

18 years of age All Phase N/A
L Lauren Theilen, MD

Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy

Cardiovascular disease is the leading cause of death among women in the United States, and women with hypertensive disorders of pregnancy have a 2-fold higher risk for cardiovascular disease later in life compared to women with uncomplicated pregnancies. This research investigates a patient-centered intervention during the postpartum period to promote …

18 years of age Female Phase N/A

Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children

This single-site research study will pilot-test a context-specific cardiovascular disease (CVD) risk prevention program, Mom♥Health, using two childhood centers at Family Health Centers (FHC) at NYU Langone as platforms for maternal engagement.

21 - 49 years of age Female Phase N/A
A Annamaria Colao, Prof

LOng COvid COmorbidities: Endocrine,Metabolic,Neuropsychiatric,Muscle,Cardiovascular,Pulmonary,Dermatologic Dysfunctions

Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of SARS-CoV-2 infection, the purpose of the study is to investigate whether in patients recovered from COVID-19 disease, …

18 years of age All Phase N/A
B Barry Borlaug

Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction

The purpose of this study is to internally validate low-field Ex-CMR as a noninvasive tool for diagnosing, phenotyping, and risk stratifying HFpEF in patients with exertional dyspnea.

18 - 80 years of age All Phase N/A
A Alexander Egbe, MBBS, MPH

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.

18 years of age All Phase 3
c chi fu chiang, Ph.D

The Efficacy Evaluation of Buckwheat Husk Extract on Cardiovascular Disease Risk Factors

To assess the efficacy evaluation of buckwheat husk extract on cardiovascular disease risk factors

20 - 65 years of age All Phase N/A

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin …

45 - 80 years of age All Phase N/A

Simplify language using AI